The FDA Just Approved a New Drug for an Aggressive Form of Prostate Cancer — and It Targets the Disease in a Way No Approved ...
According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime. In addition, about 1 in 44 men will die from the disease, ...
Cancer cells are remarkably good at adapting to stress. When treatments damage them, they often find new ways to survive, ...
A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer resistance to enzalutamide, a frequently used drug. The article is published in ...
Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers. The discovery, published Dec. 13 in ...
A medicinal plant widely used in Ghana for prostate disorders may help slow the growth of prostate cancer by blocking the ...
A newly identified interaction between PIM1 and HMGB1 helps prostate cancer cells survive therapy by activating cellular ...
Prostate cancer is a multifactorial disease influenced by various molecular features. Over the past decades, epigenetics, which is the study of changes in gene expression without altering the DNA ...
Despite extensive prior research on prostate cancer (PCa) transcriptomics, the molecular mechanisms underlying the disease’s progression, particularly in the castration-resistant or metastatic stages, ...
Prostate cancer is one of the most common cancers and the second leading cause of cancer-related death in men worldwide. However, the mechanisms controlling the early stages of prostate cancer ...
A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer ...
Real-world ASCO data link GLP-1 drugs to markedly longer survival across common cancers, raising new questions on mechanism and trials. Patients with cancer who used glucagon-like peptide-1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results